- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06100887
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy (FOX)
A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
FOX is a 2-part, multi-center, Phase 2 study to evaluate the effect of EDG-5506 on safety, pharmacokinetics and biomarkers of muscle damage in approximately 24 children and adolescents with Duchenne muscular dystrophy treated with oral, once-daily EDG-5506.This study will have up to a 4-week Screening period, a 12-week randomized double-blind, placebo-controlled treatment period (Part A), followed by a 40-week open-label extension period (Part B) .
Approximately twenty-four (24) participants aged 6 to 14, inclusive, will be randomized to EDG-5506 or placebo in a 2:1 ratio. Two dose cohorts (Cohort 1 and Cohort 2) of approximately 12 participants each will be enrolled.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Edgewise Therapeutics
- Phone Number: 720-262-7002
- Email: studies@edgewisetx.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA Medical Center
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- Recruiting
- University of Massachusetts Memorial Medical Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
-
North Carolina
-
Hillsborough, North Carolina, United States, 27278
- Recruiting
- Rare Disease Research
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Aged 6 to 14 with a documented mutation on the DMD gene and phenotype consistent with DMD.
- Prior receipt of an AAV-based gene therapy (≥ 2 years after study drug administration in an open-label study or ≥ 3 years after randomization in a randomized study).
- Able to complete stand from supine in ≤ 8 seconds at the Screening visit and able to perform the 4-stair climb in < 10 seconds at the Screening visit.
- Body weight ≥ 20 kg at the Screening visit.
- Treatment with a stable dose of corticosteroids for a minimum of 6 months prior to the Baseline visit.
Key Exclusion Criteria:
- Medical history or clinically significant physical exam/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes venous access that would be too difficult to facilitate repeated blood sampling.
- Screening visit cardiac echocardiography showing left ventricular ejection fraction (LVEF) < 40%.
- Receipt of an investigational drug (other than the AAV-based gene therapy per Inclusion criteria) within 30 days or 5 half-lives (whichever is longer) of the Screening visit in the present study.
- Receipt of an exon-skipping therapy within 6 months prior to the Screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Drug: EDG-5506 Drug: Placebo
|
EDG-5506 is administered orally once per day
Placebo is administered orally once per day
|
Experimental: Cohort 2
Drug: EDG-5506 Drug: Placebo
|
Placebo is administered orally once per day
EDG-5506 is administered orally once per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events during treatment with EDG-5506 or placebo
Time Frame: 12 months
|
All participants
|
12 months
|
Severity of adverse events during treatment with EDG-5506 or placebo
Time Frame: 12 months
|
All participants
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of abnormal clinical chemistry test results
Time Frame: 12 months
|
All participants
|
12 months
|
Incidence of abnormal hematology test results
Time Frame: 12 months
|
All participants
|
12 months
|
Incidence of abnormal coagulation test results
Time Frame: 12 months
|
All participants
|
12 months
|
Incidence of abnormal urinalysis test results
Time Frame: 12 months
|
All participants
|
12 months
|
Pharmacokinetics as measured by steady state plasma concentration
Time Frame: 12 months
|
All participants
|
12 months
|
Change from Baseline in fast skeletal muscle troponin I
Time Frame: 12 weeks
|
All participants
|
12 weeks
|
Change from Baseline in serum creatine kinase
Time Frame: 12 weeks
|
All participants
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Sam Collins, MBBS, PhD, Edgewise Therapeutics, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EDG-5506-215
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
-
Ondokuz Mayıs UniversityCompletedDuchenne Muscular Dystrophy (DMD)Turkey
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Parent Project, ItalyCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
GenethonInstitute of MyologyCompletedDuchenne Muscular Dystrophy (DMD)France
-
Ann & Robert H Lurie Children's Hospital of ChicagoChildren's National Research InstituteWithdrawnDuchenne Muscular Dystrophy (DMD)United States
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
Clinical Trials on EDG-5506 Dose 1
-
Edgewise Therapeutics, Inc.RecruitingDuchenne Muscular DystrophyUnited States
-
Edgewise Therapeutics, Inc.CompletedNervous System Diseases | Genetic Diseases, Inborn | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Healthy VolunteerUnited States
-
Edgewise Therapeutics, Inc.Medpace, Inc.Enrolling by invitationBecker Muscular DystrophyUnited States, Netherlands
-
Edgewise Therapeutics, Inc.Medpace, Inc.; SYSNAV; ImagingNMDRecruitingBecker Muscular DystrophyUnited States, Netherlands, United Kingdom
-
Edgewise Therapeutics, Inc.Medpace, Inc.Active, not recruitingBecker Muscular DystrophyUnited States
-
Edgewise Therapeutics, Inc.CompletedMuscular DystrophiesUnited States
-
Edgewise Therapeutics, Inc.Worldwide Clinical TrialsCompletedBecker Muscular Dystrophy | Healthy VolunteerUnited States
-
Medy-ToxCompletedLateral Canthal Lines | Glabellar LinesUnited States, Russian Federation, Germany, Canada, Belgium, United Kingdom
-
Zensun Sci. & Tech. Co., Ltd.Zensun USA Inc.CompletedChronic Heart FailureUnited States
-
Astellas Pharma Europe B.V.CompletedPharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707France